BIVI vs. ENLV, AYTU, CLRB, PMVP, VSTM, CLSD, LFVN, PRPH, ETON, and TLSA
Should you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Enlivex Therapeutics (ENLV), Aytu BioPharma (AYTU), Cellectar Biosciences (CLRB), PMV Pharmaceuticals (PMVP), Verastem (VSTM), Clearside Biomedical (CLSD), LifeVantage (LFVN), ProPhase Labs (PRPH), Eton Pharmaceuticals (ETON), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical preparations" industry.
Enlivex Therapeutics (NASDAQ:ENLV) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment.
Enlivex Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
In the previous week, Enlivex Therapeutics had 2 more articles in the media than BioVie. MarketBeat recorded 5 mentions for Enlivex Therapeutics and 3 mentions for BioVie. Enlivex Therapeutics' average media sentiment score of 1.27 beat BioVie's score of 0.95 indicating that BioVie is being referred to more favorably in the news media.
Enlivex Therapeutics received 33 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 64.00% of users gave BioVie an outperform vote.
1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 4.8% of BioVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
BioVie's return on equity of -71.00% beat Enlivex Therapeutics' return on equity.
Enlivex Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.
Enlivex Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 434.35%. BioVie has a consensus price target of $8.00, suggesting a potential upside of 1,728.99%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe BioVie is more favorable than Enlivex Therapeutics.
Summary
Enlivex Therapeutics beats BioVie on 9 of the 14 factors compared between the two stocks.
Get BioVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
